Xia Y, Uhlén S, Chhajlani V, Lien E J, Wikberg J E
Department of Pharmacology, Umeå University, Sweden.
Pharmacol Toxicol. 1993 Jan;72(1):40-9. doi: 10.1111/j.1600-0773.1993.tb01337.x.
Analysis of saturation isotherms of the novel alpha 2-adrenoceptor antagonist radioligand [3H]-MK 912 revealed that the ligand labelled a homogenous population of alpha 2B-adrenoceptors in the neonatal rat lung with a Kd of 0.77 nM and a Bmax of 231 fmol/mg protein. In rat kidney, combined saturation and competition experiments, using [3H]-MK 912 and the alpha 2A-adrenoceptor selective drug guanfacine, revealed that approximately 81% of the sites labelled by [3H]-MK 912 were alpha 2B-adrenoceptors and approximately 19% alpha 2A-adrenoceptors; the Kds of [3H]-MK 912 being 1.1 and 2.0 nM and the Bmax 134 and 33 fmol/mg protein, respectively. The kidney alpha 2B-adrenoceptors were studied separately by using approximately 1.5 nM [3H]-MK 912 in the presence of 0.32 microM guanfacine, the latter which blocked ligand binding to alpha 2A-adrenoceptors completely. Analysis of drug competition curves obtained during these conditions revealed that 18 out of 20 different agonists and antagonists yielded steep and uniphasic competition curves which modelled best into one site fits. However, both guanoxabenz and LT 11 appeared to inhibit [3H]-MK 912 binding at two sites; the Kds of guanoxabenz differing approximately 120-fold and that of LT 11 differing approximately 35-fold for the two sites. Moreover, the addition of mutual fixed concentrations of either 20 microM guanoxabenz or 20 microM LT 11 completely prevented the binding of the other compound to its high affinity site, indicating that both compounds labelled the same site with the high affinity. The analysis indicated that 29% of the sites were of high and 71% of low affinity. However, in the neonatal rat lung guanoxabenz and LT 11 (as well as 15 other compounds) yielded competition curves which modelled only into one site fits. The Kds obtained in the lung correlated well with the Kds obtained in the kidney for alpha 2B-adrenoceptors; for guanoxabenz and LT 11 the values from the lung were close to those determined in the kidney for the low affinity site for guanoxabenz and LT 11. Moreover, when the rat RNG alpha 2B-adrenoceptor was expressed in COS-7 cells and its binding properties tested using [3H]-MK 912 binding, guanoxabenz, LT 11 as well as a number of other drugs inhibited the ligand binding at a single alpha 2-adrenoceptor site; the drug Kds being practically the same as those found for the neonatal rat lung. It is suggested that rat alpha 2B-adrenoceptors may exist in two forms: alpha 2B1 and alpha 2B2.(ABSTRACT TRUNCATED AT 400 WORDS)
新型α2-肾上腺素能受体拮抗剂放射性配体[3H]-MK 912的饱和等温线分析表明,该配体标记新生大鼠肺中α2B-肾上腺素能受体的同质群体,解离常数(Kd)为0.77 nM,最大结合容量(Bmax)为231 fmol/mg蛋白质。在大鼠肾脏中,使用[3H]-MK 912和α2A-肾上腺素能受体选择性药物胍法辛进行联合饱和与竞争实验,结果显示,[3H]-MK 912标记的位点中约81%为α2B-肾上腺素能受体,约19%为α2A-肾上腺素能受体;[3H]-MK 912的Kd分别为1.1和2.0 nM,Bmax分别为134和33 fmol/mg蛋白质。通过在0.32 μM胍法辛存在下使用约1.5 nM [3H]-MK 912分别研究肾脏α2B-肾上腺素能受体,后者可完全阻断配体与α2A-肾上腺素能受体的结合。对这些条件下获得的药物竞争曲线分析表明,20种不同激动剂和拮抗剂中的18种产生陡峭且单相的竞争曲线,最适合单一位点拟合。然而,胍那苄和LT 11似乎在两个位点抑制[3H]-MK 912结合;胍那苄在两个位点的Kd相差约120倍,LT 11相差约35倍。此外,添加相互固定浓度的20 μM胍那苄或20 μM LT 11可完全阻止另一种化合物与其高亲和力位点的结合,表明两种化合物在高亲和力位点标记相同位点。分析表明,29%的位点具有高亲和力,71%具有低亲和力。然而,在新生大鼠肺中,胍那苄和LT 11(以及其他15种化合物)产生的竞争曲线仅适合单一位点拟合。在肺中获得的Kd与在肾脏中获得的α2B-肾上腺素能受体的Kd相关性良好;对于胍那苄和LT 11,肺中的值接近在肾脏中测定的胍那苄和LT 11低亲和力位点的值。此外,当大鼠RNG α2B-肾上腺素能受体在COS-7细胞中表达并使用[3H]-MK 912结合测试其结合特性时,胍那苄、LT 11以及其他多种药物在单个α2-肾上腺素能受体位点抑制配体结合;药物Kd与在新生大鼠肺中发现的实际相同。提示大鼠α2B-肾上腺素能受体可能以两种形式存在:α2B1和α2B2。(摘要截短于四百字)